Literature DB >> 16821794

Kinetics and mechanisms of activation of alpha-amino acid ester prodrugs of camptothecins.

Lin Song1, Robert Bevins, Bradley D Anderson.   

Abstract

The alpha-amino acid ester prodrugs of the antitumor agent camptothecin and a more potent, lipophilic silatecan analogue, DB-67, have been shown by NMR spectroscopy and quantitative kinetic analyses to undergo quantitative conversion to their pharmacologically active lactones via a nonenzymatic mechanism that at pH 7.4 is favored over direct hydrolysis. The alternate pathway involves the reversible intramolecular nucleophilic amine attack at the camptothecin E-ring carbonyl to generate a lactam (I) followed by a second intramolecular reaction to produce a bicyclic hemiortho ester (I'). The intermediates were isolated and shown to exist in an apparent equilibrium dominated by the hemiortho ester in DMSO using NMR spectroscopy. The conversion of prodrugs of camptothecin or DB-67 containing either alpha-NH(2) or alpha-NHCH(3) and their corresponding hemiortho esters were monitored versus time in aqueous buffer (pH 3.0 and 7.4) at 37 degrees C, and the kinetic data were fit to a model based on the proposed mechanism. The results indicated that while the prodrugs are relatively stable at pH 3, facile lactone release occurs from both the prodrugs and their corresponding hemiortho ester intermediates under physiological conditions (pH 7.4). The glycinate esters and their hemiortho esters were found to be more cytotoxic than the N-methylglycinates or their corresponding hemiortho ester intermediates in vitro using a human breast cancer cell line (MDA-MB-435S), consistent with their more rapid conversion to active lactone. The pH dependence of the nonenzymatic pathway for conversion of these alpha-amino acid ester prodrugs suggests that they may be useful for tumor-targeting via liposomes, as they can be stabilized in an acidic environment in the core of liposomes and readily convert to the active lactone following their intratumoral release.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16821794      PMCID: PMC2516925          DOI: 10.1021/jm060016l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  27 in total

1.  Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.

Authors:  G T Colbern; D J Dykes; C Engbers; R Musterer; A Hiller; E Pegg; R Saville; S Weng; M Luzzio; P Uster; M Amantea; P K Working
Journal:  Clin Cancer Res       Date:  1998-12       Impact factor: 12.531

2.  Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.

Authors:  Z Cao; N Harris; A Kozielski; D Vardeman; J S Stehlin; B Giovanella
Journal:  J Med Chem       Date:  1998-01-01       Impact factor: 7.446

3.  Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.

Authors:  R M Wadkins; P M Potter; B Vladu; J Marty; G Mangold; S Weitman; G Manikumar; M C Wani; M E Wall; D D Von Hoff
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

4.  On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex.

Authors:  R P Hertzberg; M J Caranfa; S M Hecht
Journal:  Biochemistry       Date:  1989-05-30       Impact factor: 3.162

5.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

Authors:  Y H Hsiang; M G Lihou; L F Liu
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

6.  Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity.

Authors:  R B Greenwald; A Pendri; C D Conover; C Lee; Y H Choe; C Gilbert; A Martinez; J Xia; D Wu; M Hsue
Journal:  Bioorg Med Chem       Date:  1998-05       Impact factor: 3.641

7.  A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues.

Authors:  J Fassberg; V J Stella
Journal:  J Pharm Sci       Date:  1992-07       Impact factor: 3.534

8.  Strategies in the design of solution-stable, water-soluble prodrugs I: a physical-organic approach to pro-moiety selection for 21-esters of corticosteroids.

Authors:  B D Anderson; R A Conradi; K E Knuth
Journal:  J Pharm Sci       Date:  1985-04       Impact factor: 3.534

9.  Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice.

Authors:  William C Zamboni; Laura L Jung; Sandra Strychor; Erin Joseph; Beth A Zamboni; Sarah A Fetterman; Brian J Sidone; Thomas G Burke; Dennis P Curran; Julie L Eiseman
Journal:  Invest New Drugs       Date:  2008-02-02       Impact factor: 3.850

10.  Differential interactions of camptothecin lactone and carboxylate forms with human blood components.

Authors:  Z Mi; T G Burke
Journal:  Biochemistry       Date:  1994-08-30       Impact factor: 3.162

View more
  2 in total

Review 1.  Cyclization-activated prodrugs.

Authors:  Paula Gomes; Nuno Vale; Rui Moreira
Journal:  Molecules       Date:  2007-11-12       Impact factor: 4.411

2.  A series of alpha-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity.

Authors:  Manjeet Deshmukh; Piyun Chao; Hilliard L Kutscher; Dayuan Gao; Patrick J Sinko
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.